Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12â300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.

De Castro, Nathalie; Marcy, Olivier; Chazallon, Corine; Messou, Eugène; Eholié, Serge; N'takpe, Jean-Baptiste; Bhatt, Nilesh; Khosa, Celso; Timana Massango, Isabel; Laureillard, Didier; Chau, Giang Do; Domergue, Anaïs; Veloso, Valdilea; Escada, Rodrigo; Wagner Cardoso, Sandra; Delaugerre, Constance; Anglaret, Xavier; Molina, Jean-Michel; Grinsztejn, Beatriz

Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12â300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.

De Castro, Nathalie; Marcy, Olivier; Chazallon, Corine; Messou, Eugène; Eholié, Serge; N'takpe, Jean-Baptiste; Bhatt, Nilesh; Khosa, Celso; Timana Massango, Isabel; Laureillard, Didier; Chau, Giang Do; Domergue, Anaïs; Veloso, Valdilea; Escada, Rodrigo; Wagner Cardoso, Sandra; Delaugerre, Constance; Anglaret, Xavier; Molina, Jean-Michel; Grinsztejn, Beatriz.

Affiliation

De Castro N; Department of Infectious Diseases, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France; Bordeaux Population Health Research Center, UMR 1219, INSERM, University of Bordeaux, French National Research Institute for Sustainable Development, Bordeaux, France. Electronic address: na
Marcy O; Bordeaux Population Health Research Center, UMR 1219, INSERM, University of Bordeaux, French National Research Institute for Sustainable Development, Bordeaux, France.
Chazallon C; Bordeaux Population Health Research Center, UMR 1219, INSERM, University of Bordeaux, French National Research Institute for Sustainable Development, Bordeaux, France.
Messou E; Centre de Prise en charge de Recherche et de Formation, Abidjan, Côte d'Ivoire; Programme PACCI/ANRS Research Center, Abidjan, Cote d'Ivoire; Département de Dermatologie et d'Infectiologie, Unite de Formation et de Recherche des Sciences Médicales, Université Félix Houphouët Boigny, Abidjan, Cote d'
Eholié S; Programme PACCI/ANRS Research Center, Abidjan, Cote d'Ivoire; Département de Dermatologie et d'Infectiologie, Unite de Formation et de Recherche des Sciences Médicales, Université Félix Houphouët Boigny, Abidjan, Cote d'Ivoire.
N'takpe JB; Programme PACCI/ANRS Research Center, Abidjan, Cote d'Ivoire.
Bhatt N; Instituto Nacional de Saúde, Marracuene, Mozambique.
Khosa C; Instituto Nacional de Saúde, Marracuene, Mozambique.
Timana Massango I; Instituto Nacional de Saúde, Marracuene, Mozambique.
Laureillard D; Research Unit 1058 Pathogenesis and Control Chronical Infections, INSERM, French Blood Center, University of Montpellier, Montpellier, France; Department of Infectious and Tropical Diseases, Nimes University Hospital, Nimes, France.
Chau GD; General Planning Department, Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam.
Domergue A; National Agency for Research on AIDS and Viral Hepatitis Research Site, Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam.
Veloso V; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Escada R; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Wagner Cardoso S; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Delaugerre C; Department of Virology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France; INSERM U944, Université de Paris, Paris, France.
Anglaret X; Bordeaux Population Health Research Center, UMR 1219, INSERM, University of Bordeaux, French National Research Institute for Sustainable Development, Bordeaux, France; Centre de Prise en charge de Recherche et de Formation, Abidjan, Côte d'Ivoire.
Molina JM; Department of Infectious Diseases, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France; INSERM U944, Université de Paris, Paris, France.
Grinsztejn B; National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.

Lancet Infect Dis ; 21(6): 813-822, 2021 06.

Article de En | MEDLINE | ID: mdl-33667406

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tuberculose / Infections à VIH / Agents antiVIH / Cyclopropanes / Benzoxazines / Alcynes / Co-infection / Raltégravir de potassium Type d'étude: Clinical_trials Limites: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Pays/Région comme sujet: Africa / America do sul / Asia / Brasil / Europa Langue: En Journal: Lancet Infect Dis Sujet du journal: DOENCAS TRANSMISSIVEIS Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google